Description

Microarray Panel:Ovary cancer No. of samples59No. of patients59Core diameter2.0 mmFormat:Formalin FixedSection thickness 4 micrometer Core# No. Age Sex Organ Diagnosis pTNM Stage Tissuetype Image 1 65 F Ovary serous papillary cystadenoma of borderline malignancy T1aN0M0 I A 5 " class="fd_image"> 2 26 F Ovary mucinous cystadenoma of borderline malignancy T1aN0M0 I A 5 " class="fd_image"> 3 35 F Ovary serous papillary cystadenoma of borderline malignancy T1aN0M0 I A 5 " class="fd_image"> 4 65 F Ovary serous cystadenocarcinoma T2bN0M0 IIB 6 " class="fd_image"> 5 48 F Ovary endometrioid carcinoma T2bN0M0 IIB 6 " class="fd_image"> 6 44 F Ovary granulosa cell tumor T1aN0M0 I A 5 " class="fd_image"> 7 49 F Ovary endometrioid carcinoma T2bN0M0 IIB 6 " class="fd_image"> 8 67 F Ovary mucinous cystadenoma of borderline malignancy T2bN0M0 IIB 5 " class="fd_image"> 9 75 F Ovary serous cystadenofibroma T1aN0M0 I A 4 " class="fd_image"> 10 50 F Ovary papillary serous cystadenocarcinoma, poorly differentiated T2cN0M0 IIC 6 " class="fd_image"> 11 44 F Ovary fibroma T1aN0M0 I A 4 " class="fd_image"> 12 50 F Ovary papillary serous cystadenocarcinoma T3cN0M1 IV 6 " class="fd_image"> 13 47 F Ovary endometrioid carcinoma T3cN0M1 IV 6 " class="fd_image"> 14 38 F Ovary mixed Brenner tumor and mucinous cystadenoma T1aN0M0 I A 4 " class="fd_image"> 15 58 F Ovary papillary serous cystadenocarcinoma T2bN0M0 IIB 6 " class="fd_image"> 16 70 F Ovary papillary serous cystadenocarcinoma T3bN0M0 IIIB 6 " class="fd_image"> 17 65 F Ovary struma ovarii T1aN0M0 I A 4 " class="fd_image"> 18 79 F Ovary endometrioid adenoacanthofibroma T1aN0M0 I A 4 " class="fd_image"> 19 57 F Ovary serous surface papillary carcinoma T2bN0M0 IIB 6 " class="fd_image"> 20 43 F Ovary papillary serous cystadenocarcinoma T3bN0M0 IIIB 6 " class="fd_image"> 21 68 F Ovary undifferentiated carcinoma T1bN0M0 I B 6 " class="fd_image"> 22 50 F Ovary clear cell carcinoma T1aN0M0 I A 6 " class="fd_image"> 23 23 F Ovary dysgerminoma T2bN0M0 IIB 6 " class="fd_image"> 24 51 F Ovary common epithelial carcinoma, poorly differentiated T2bN0M0 IIB 6 " class="fd_image"> 25 70 F Ovary malignant muellerian mixed tumor T1aN0M0 I A 6 " class="fd_image"> 26 21 F Ovary dysgerminoma T1aN0M0 I A 6 " class="fd_image"> 27 34 F Ovary fibrothecoma T1aN0M0 I A 4 " class="fd_image"> 28 61 F Ovary papillary serous cystadenocarcinoma T3bN0M0 IIIB 6 " class="fd_image"> 29 54 F Ovary sertoli-leydig cell tumor T1bN0M0 IB 4 " class="fd_image"> 30 53 F Ovary fibrothecoma T1aN0M0 I A 4 " class="fd_image"> 31 54 F Ovary fibrothecoma T1aN0M0 I A 4 " class="fd_image"> 32 34 F Ovary papillary serous cystadenocarcinoma T2bN0M0 IIB 6 " class="fd_image"> 33 31 F Ovary dysgerminoma T2cN0M0 IIC 6 " class="fd_image"> 34 51 F Ovary papillary serous cystadenocarcinoma T2bN1M0 IIIC 6 " class="fd_image"> 35 61 F Ovary granulosa-theca cell tumor T1aN0M0 I A 5 " class="fd_image"> 36 24 F Ovary sertoli-leydig cell tumor T1aN0M0 I A 4 " class="fd_image"> 37 27 F Ovary sclerosing stromal tumor T1aN0M0 I A 5 " class="fd_image"> 38 41 F Ovary clear cell carcinoma T2bN0M0 IIB 6 " class="fd_image"> 39 56 F Ovary malignant muellerian mixed tumor T1aN0M0 I A 6 " class="fd_image"> 40 41 F Ovary clear cell carcinoma T1aN0M0 I A 6 " class="fd_image"> 41 27 F Ovary embryonal carcinoma T2aN0M0 II A 6 " class="fd_image"> 42 55 F Ovary granulosa cell tumor T1aN0M0 I A 5 " class="fd_image"> 43 23 F Ovary dysgerminoma T1aN0M0 I A 6 " class="fd_image"> 44 64 F Ovary papillary serous cystadenocarcinoma T2cN1M0 IIIC 5 " class="fd_image"> 45 43 F Ovary metastatic adenocarcinoma (most likely from breast) M1 IV 6 " class="fd_image"> 46 48 F Ovary malignant lymphoma . II 6 " class="fd_image"> 47 50 F Ovary adenocarcinoma from salpinx T2bN0M0 IIB 6 " class="fd_image"> 48 25 F Ovary fibrothecoma T1aN0M0 IA 4 " class="fd_image"> 49 46 F Ovary metastatic undifferentiated carcinoma M1 IV 6 " class="fd_image"> 50 37 F Ovary metastatic signet ring carcinoma from stomach M1 IV 6 " class="fd_image"> 51 55 F Ovary serous cystadenocarcinoma, moderatelydifferentiated T3bN0M0 IIIB 6 " class="fd_image"> 52 55 F Ovary fibrothecoma T1aN0M0 I A 4 " class="fd_image"> 53 45 F Ovary serous cystadenocarcinoma, moderatelydifferentiated T2cN0M0 IIC 6 " class="fd_image"> 54 37 F Ovary endometrioid carcinoma T2bN0M0 IIB 6 " class="fd_image"> 55 58 F Ovary fibrothecoma T1aN0M0 I A 4 " class="fd_image"> 56 65 F Ovary adenocarcinoma, poorly differentiated T3cN0M0 IIIC 6 " class="fd_image"> 57 39 F Ovary clear cell carcinoma T2cN1M0 IIIC 6 " class="fd_image"> 58 70 F Ovary fibroma T1aN0M0 I A 4 " class="fd_image"> 59 58 F Ovary clear cell carcinoma T1aN0M0 I A 6 " class="fd_image"> 60 . . Carbon . . . . " alt="" class="fd_image">

Publications

ReadPublications using NBP2-30290.

Novus Biologicals北京代理，Novus Biologicals中国代理，Novus Biologicals上海代理，Novus Biologicals公司，Novus Biologicals 【详细说明】  Novus Biologicals北京代理，Novus Biologicals中国代理，Novus Biologicals上海代理，Novus Biologicals公司，Novus Biologicals 上海普迈生物科技有限公司签约代理      欢迎下载下面的资料以了解此产品的相关信息！预询产品订购信息  上海普迈生物致力于提供zui高质量的产品和服务组织形态学研究与竞争力的产品 产品和服务,有相关产品的问题请直接 期货每周下午5点前发定单，正常到上海时间为3-4周 现市区2天内送到，外地以快递为准 敬请关注！ ：   :www.pumaibio.com :pumaibio :（直接客户） （经销商） 促销etonbio、polysciences、Mattek、trevigen、Chromogenix、cyguns、IrvineScientific、Innovative Cell Technologies、enzo、novus、immunochemistry、eylabs、Polyplus、NIBSC、ALZET、hitobiotec、sutter instrument、mirus、StressMarq、Avanti、jena bioscience、Neuro Probe、tedpella、avanti、Rockland、CAYMAN、transgenomic、BioLegend、ambion、omicronbio、 Assaybiotech、chondrex、lc?laboratories、cosmobio、megazyme、NeoMarkers、BTI、eylabs、berryassoc、cellagentech、TOCRIS、Relia Tech、SouthernBiotech、Biosearch technology、Lumiprobe、StemCells?Inc、biovendor、NORGEN、alomone、jena?bioscience、Gracebio、Eurogentec、Gelcompany?、invitrogen、gene?bridges、MRC-Holland、laysanbio